HCRI’s founder and renowned medical researcher, Prof. Michal, recently featured in a compelling interview on ‘Hadassah On Call: New Frontiers in Medicine, Season 4, Episode 8’, titled ‘Melanoma: Latest on Cures, Causes, and Vaccines.’ Prof. Michal offered an insightful discussion regarding the evolving fight against skin cancer, presenting state-of-the-art prevention methods, recognition techniques, and innovative treatments.
Prof. Michal spoke at length about an exhilarating new collaboration centered around mRNA technology, the same groundbreaking approach utilized to develop the world’s first COVID-19 vaccine. In this consortium, Prof. Michal and her colleagues aim to leverage mRNA technology to revolutionize the treatment of cancer, potentially leading to a new era of personalized medicine.
One part of this ambitious consortium is working towards creating a cancer vaccine, mirroring the urgency and success seen in COVID-19 mRNA vaccine development. On the other hand, members like Prof. Lotem and her team are working diligently on novel cell therapies. These endeavors are designed to increase the likelihood of cancers responding to immune strategies, offering a ray of hope for numerous patients worldwide.
Prof. Michal passionately shared her belief in the potential of RNA technology, emphasizing the rapidity and adaptability of RNA templates. “RNA technology is an exciting frontier in cancer treatment, as it could pave the way for better and more personalized treatments,” said Prof. Michal. This fast-paced alteration capability could lead to tailoring treatment plans to specific patients, enhancing efficacy while minimizing side effects.
As we push forward into this exciting frontier of cancer treatment, Prof. Michal’s insights underscore the essential role that collaboration, technology, and research play in finding effective solutions. HCRI remains committed to innovating and advancing cancer treatment strategies and expresses gratitude for the dedication and expertise that Prof. Michal continues to contribute to this mission.
Read more
Click here for the interview
